Cargando…
Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
PURPOSE: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting. PATIENTS AND METHODS: Medical records of 130,547...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708874/ https://www.ncbi.nlm.nih.gov/pubmed/26793004 http://dx.doi.org/10.2147/JAA.S97973 |
_version_ | 1782409564511010816 |
---|---|
author | Price, David Wilson, Andrew M Chisholm, Alison Rigazio, Anna Burden, Anne Thomas, Michael King, Christine |
author_facet | Price, David Wilson, Andrew M Chisholm, Alison Rigazio, Anna Burden, Anne Thomas, Michael King, Christine |
author_sort | Price, David |
collection | PubMed |
description | PURPOSE: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting. PATIENTS AND METHODS: Medical records of 130,547 asthma patients aged 12–80 years from the UK Optimum Patient Care Research Database and Clinical Practice Research Datalink, 1990–2013, were examined for 1 year before (baseline) and 1 year after (outcome) their most recent blood eosinophil count. Baseline variables predictive (P<0.05) of exacerbation in the outcome year were compared between patients who had two or more exacerbations and those who had no exacerbation or only one exacerbation, using uni- and multivariable logistic regression models. Exacerbation was defined as asthma-related hospital attendance/admission (emergency or inpatient) or acute oral corticosteroid (OCS) course. RESULTS: Blood eosinophil count >400/µL (versus ≤400/µL) increased the likelihood of two or more exacerbations >1.4-fold (odds ratio [OR]: 1.48 (95% confidence interval [CI]: 1.39, 1.58); P<0.001). Variables that significantly increased the odds by up to 1.4-fold included increasing age (per year), female gender (versus male), being overweight or obese (versus normal body mass index), being a smoker (versus nonsmoker), having anxiety/depression, diabetes, eczema, gastroesophageal reflux disease, or rhinitis, and prescription for acetaminophen or nonsteroidal anti-inflammatory drugs. Compared with treatment at British Thoracic Society step 2 (daily controller ± reliever), treatment at step 0 (none) or 1 (as-needed reliever) increased the odds by 1.2- and 1.6-fold, respectively, and treatment at step 3, 4, or 5 increased the odds by 1.3-, 1.9-, or 3.1-fold, respectively (all P<0.05). Acute OCS use was the single best predictor of two or more exacerbations. Even one course increased the odds by more than threefold (OR: 3.75 [95% CI: 3.50, 4.01]; P<0.001), and three or more courses increased the odds by >25-fold (OR: 25.7 [95% CI: 23.9, 27.6]; P<0.001). CONCLUSION: Blood eosinophil count and several other variables routinely available in patient records may be used to predict frequent asthma exacerbations. |
format | Online Article Text |
id | pubmed-4708874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47088742016-01-20 Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice Price, David Wilson, Andrew M Chisholm, Alison Rigazio, Anna Burden, Anne Thomas, Michael King, Christine J Asthma Allergy Original Research PURPOSE: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting. PATIENTS AND METHODS: Medical records of 130,547 asthma patients aged 12–80 years from the UK Optimum Patient Care Research Database and Clinical Practice Research Datalink, 1990–2013, were examined for 1 year before (baseline) and 1 year after (outcome) their most recent blood eosinophil count. Baseline variables predictive (P<0.05) of exacerbation in the outcome year were compared between patients who had two or more exacerbations and those who had no exacerbation or only one exacerbation, using uni- and multivariable logistic regression models. Exacerbation was defined as asthma-related hospital attendance/admission (emergency or inpatient) or acute oral corticosteroid (OCS) course. RESULTS: Blood eosinophil count >400/µL (versus ≤400/µL) increased the likelihood of two or more exacerbations >1.4-fold (odds ratio [OR]: 1.48 (95% confidence interval [CI]: 1.39, 1.58); P<0.001). Variables that significantly increased the odds by up to 1.4-fold included increasing age (per year), female gender (versus male), being overweight or obese (versus normal body mass index), being a smoker (versus nonsmoker), having anxiety/depression, diabetes, eczema, gastroesophageal reflux disease, or rhinitis, and prescription for acetaminophen or nonsteroidal anti-inflammatory drugs. Compared with treatment at British Thoracic Society step 2 (daily controller ± reliever), treatment at step 0 (none) or 1 (as-needed reliever) increased the odds by 1.2- and 1.6-fold, respectively, and treatment at step 3, 4, or 5 increased the odds by 1.3-, 1.9-, or 3.1-fold, respectively (all P<0.05). Acute OCS use was the single best predictor of two or more exacerbations. Even one course increased the odds by more than threefold (OR: 3.75 [95% CI: 3.50, 4.01]; P<0.001), and three or more courses increased the odds by >25-fold (OR: 25.7 [95% CI: 23.9, 27.6]; P<0.001). CONCLUSION: Blood eosinophil count and several other variables routinely available in patient records may be used to predict frequent asthma exacerbations. Dove Medical Press 2016-01-07 /pmc/articles/PMC4708874/ /pubmed/26793004 http://dx.doi.org/10.2147/JAA.S97973 Text en © 2016 Price et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Price, David Wilson, Andrew M Chisholm, Alison Rigazio, Anna Burden, Anne Thomas, Michael King, Christine Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice |
title | Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice |
title_full | Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice |
title_fullStr | Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice |
title_full_unstemmed | Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice |
title_short | Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice |
title_sort | predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708874/ https://www.ncbi.nlm.nih.gov/pubmed/26793004 http://dx.doi.org/10.2147/JAA.S97973 |
work_keys_str_mv | AT pricedavid predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice AT wilsonandrewm predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice AT chisholmalison predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice AT rigazioanna predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice AT burdenanne predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice AT thomasmichael predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice AT kingchristine predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice |